Skip to main content

Prof David Kerins

Anti-platelet and anti-thrombotic therapy, vascular biology with a particular focus on the renin-angiotensin and fibrinolytic pathways, and non-invasive cardiac imaging.

Professor David Kerins 

Professor David Kerins received a BSc in Physiology in 1981 and an MB, BAO, BCh from UCC in 1984. He completed fellowships in Clinical Pharmacology and in Clinical Cardiology at Vanderbilt University, Nashville TN. Following appointments as an Associate Professor of Medicine and Chief of the Cardiology Section at Nashville VA, he was appointed as Associate Professor of Therapeutics at UCC and Consultant Physician at Mercy University Hospital in 2006, and served as Dean of the Medical School from 2007-2010. Professor Kerins is a fellow of the American Heart Association, the American College of Cardiology, the European Society of Cardiology and the American Society of Echocardiography. He is a Consultant Cardiologist and is the Clinical Director at Mercy University Hospital.

Research interests: Prof Kerins’ research has focussed on aspects of vascular biology. Initially his attention was on the process of platelet activation in the setting of coronary thrombolysis (fibrinolysis). This indicated that platelet activation did indeed occur when patients received therapeutics t-PA. These observations were followed by a series of studies in an experimental model of coronary thrombosis that demonstrated the mechanisms and extent of platelet activation and explored mechanisms to limit the deleterious effects of such platelet activation. Further studies examined the interaction between the fibrinolytic pathway and the renin-angiotensin system. They included the inititial demonstration that the angiotensin IV receptor was biologically active in regulating the expression of plasminogen activator inhibitor 1 (PAI-1). The role of the fibrinolytic pathway in organ regeneration and in the process of atherosclerosis were also the subject of many studies. Most recently these interests are applied in a study of the effects of functional food products on a variety of parameters that influence thrombosis and coagulation as part of the NationalFunctional Food Research Center grant at UCC. Prof Kerins has also developed a more clinically active interest in non-invasive cardiac imaging. This has resulted in studies to address the role of echocardiography and of magnetic resonance imaging in vascular disease. This is currently expressed in a joint study with colleagues from the Department of Rheumatology at Cork University Hospital in the evaluation of preclinical atherosclerosis in a patient population with rheumatoid arthritis.

I welcome enquires from students interested in discussing MSc or PhD opportunities. If you have ideas for collaborations on existing work or would like to discuss your own research interests then I am more than happy to discuss this with you in the first instance by email d.kerins@ucc.ie

Publications:

Walsh LJ, Collins C, Ibrahim H, Kerins DM, Brady AP, O Connor TM. (2022) Pulmonary arterial hypertension in hereditary hemorrhagic telangiectasia associated with ACVRL1 mutation: a case report. J Med Case Rep. 16(1):99. doi: 10.1186/s13256-022-03296-9.

Bakkum MJ, Richir MC, Papaioannidou P, Likic R, Sanz EJ, Christiaens T, Costa JN, Mačiulaitis R, Dima L, Coleman J, Tichelaar J, van Agtmael MA; Education Working Group of the European Association for Clinical Pharmacology and Therapeutics (EACPT) and its affiliated Network of Teachers in Pharmacotherapy (NOTIP) (2021) EurOP2E - the European Open Platform for Prescribing Education, a consensus study among clinical pharmacology and therapeutics teachers. Eur J Clin Pharmacol. 77(8):1209-1218. doi: 10.1007/s00228-021-03101-4.

Caplice NM, DeVoe MC, Choi J, Dahly D, Murphy T, Spitzer E, Van Geuns R, Maher MM, Tuite D, Kerins DM, Ali MT, Kalyar I, Fahy EF, Khider W, Kelly P, Kearney PP, Curtin RJ, O'Shea C, Vaughan CJ, Eustace JA, McFadden EP. (2018) Randomized placebo controlled trial evaluating the safety and efficacy of single low-dose intracoronary insulin-like growth factor following percutaneous coronary intervention in acute myocardial infarction (RESUS-AMI). Am Heart J. 200:110-117. doi: 10.1016/j.ahj.2018.03.018. Epub 2018 Apr 3.

Walsh E, Sahm LJ, Kearney PM, Smithson H, Kerins DM, Ngwa C, Fitzgerald C, Mc Carthy S, Connolly E, Dalton K, Byrne D, Carey M, Bradley C. (2018) The PHARMS (Patient Held Active Record of Medication Status) feasibility study: a research proposal. BMC Res Notes. 11(1):6. doi: 10.1186/s13104-017-3118-3.

McCarthy CP, Mullins KV, Kerins DM. (2015) The role of trimetazidine in cardiovascular disease: beyond an anti-anginal agent. Eur Heart J Cardiovasc Pharmacother. 2(4):266-72. doi: 10.1093/ehjcvp/pvv051.

 

 

 

Department of Pharmacology and Therapeutics

Cógaseolaíocht agus Teiripic

Room 2.36B, 2nd floor floor, T12XF62

Top